Replies to post #591 on Biotech Values

[DewDiligence]

Thanks, isolution! Some comments and questions:

Slide 5: Any idea what “Supplemental Oxygen” refers to?

Slide 15: This slide is missing from your post.

Slide 17: Unlike GENR’s Squalamine trial, CA4P patients were allowed to have received prior Visudyne. I wonder how this will complicate analysis of the effect of CA4P.

Slide 18: “FA and OCT immediately after first infusion, and just prior to next 3 infusions”. I do not know what FA and OCT mean.

Slide 19: It says four patients have completed treatment, but I do not see a reference to “18 eyes” having been treated as was mentioned on the OXGN message board. Is that information in there somewhere?

Slides 20-31: If it’s not too much trouble, I would be interested in these results.

T.i.a. Dew

[DewDiligence]

Update on AMD slides from Johns Hopkins:

These are the same slides from which “isolution” extracted the relevant text in #msg-1906186 and #msg-1906935.

I just upgraded to Microsoft Office 2003 (which includes PowerPoint) and have now been able to view the actual slides. The PowerPoint file is at:

http://tinyurl.com/33mvl
[Allow a few minutes to load, especially if using dial-up internet access.]

Contents: GNVC’s AdPEDF (slides 6-11), OXGN’s CA4P (slides 12-19), Lucentis (slides 20-27), and REGN’s VEGF-Trap (slides 28-31).

Dew